New shot could help diabetics shed pounds on top of existing meds

NCT ID NCT06851858

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests an experimental drug called AZD6234, given as a weekly injection, for weight loss in adults with overweight or obesity and type 2 diabetes. Participants are already on a stable dose of a GLP-1 medication. The study will compare AZD6234 to a placebo over 26 weeks to see if it leads to greater weight loss. About 69 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6234 (weekly injection)
What this could lead to: If it works, this could offer a new option for weight loss in people with type 2 diabetes who are already on a GLP-1 medication.
What could go wrong: This is a small, early Phase 2 trial. It may not show enough benefit or could have side effects. Success in this study does not guarantee approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine system disorder Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES TYPE II ENDOCRINOLOGY OBESITY

Contacts and locations

Locations

Research Site

Birmingham, Alabama, 35205, United States
Research Site

Mobile, Alabama, 36608, United States
Research Site

Doral, Florida, 33166, United States
Research Site

Jacksonville, Florida, 32216, United States
Research Site

Miami, Florida, 33135, United States
Research Site

Miami, Florida, 33136, United States
Research Site

Winter Park, Florida, 32789, United States
Research Site

Canton, Georgia, 30114, United States
Research Site

Fayetteville, Georgia, 30214, United States
Research Site

Chicago, Illinois, 60640, United States
Research Site

Oak Brook, Illinois, 60523, United States
Research Site

Newton, Kansas, 67114, United States
Research Site

Lexington, Kentucky, 40509, United States
Research Site

Kansas City, Missouri, 64114, United States
Research Site

Las Vegas, Nevada, 89119, United States
Research Site

Norman, Oklahoma, 73069, United States
Research Site

Knoxville, Tennessee, 37909, United States
Research Site

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.